Welcome to our dedicated page for MAIA Biotechnology news (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.
MAIA Biotechnology, Inc. develops targeted immunotherapies for cancer, with news centered on its lead investigational therapy, ateganosine, also known as THIO, for non-small cell lung cancer. Company updates frequently address the THIO-101 clinical program, ateganosine’s telomere-targeting and immune-activating mechanism, use with the checkpoint inhibitor cemiplimab, and FDA Fast Track designation in third-line NSCLC.
Recurring MAIA news also includes oncology data presentations, shareholder letters on the development pipeline, clinical-site and trial-expansion updates, and financing activity tied to its clinical programs. Capital-market announcements have included common stock offerings, shelf registration use, and stated uses of proceeds for clinical trials, working capital, and general corporate purposes.
MAIA Biotechnology, Inc. has been selected to present its innovative THIO platform at the XIV International Round Table on Nucleosides in Stockholm, Sweden, from August 28 to 31, 2022. This platform showcases the modified nucleoside 6-thio-2’-deoxyguanosine (6-thio-dG) as a promising anticancer agent. The presentation will highlight how THIO may enhance immune responses and overcome therapy resistance. MAIA aims to develop THIO for non-small cell lung cancer patients resistant to existing checkpoint inhibitors.
MAIA Biotechnology, Inc. (NYSE American: MAIA) reported its second-quarter 2022 financial results, highlighting significant advancements in its clinical development of THIO, an immunotherapy for cancer. The company has initiated a Phase 2 trial for Non-Small Cell Lung Cancer (NSCLC) and received orphan drug designations from the FDA for two additional indications: Small Cell Lung Cancer (SCLC) and Hepatocellular Carcinoma (HCC). MAIA completed its IPO on August 1, raising $11.5 million, and reported a net loss of approximately $3.3 million for the quarter.
MAIA Biotechnology has received Orphan Drug Designation for THIO, its telomere-targeting agent, from the FDA. This designation applies to THIO's potential in treating small-cell lung cancer (SCLC) and builds on its previous designation for hepatocellular carcinoma (HCC). The company sees THIO as having a significant multi-billion-dollar opportunity in oncology. SCLC patients face a grim prognosis, with only 6% surviving five years post-diagnosis, highlighting the need for effective treatments.
MAIA Biotechnology, Inc. has successfully closed its initial public offering, issuing 2,000,000 shares at a price of $5.00 per share, resulting in gross proceeds of $10,000,000. The shares began trading on the NYSE American on July 28, 2022, under the ticker symbol MAIA. The proceeds will fund the Phase 2 trials of its product candidate THIO and support further development of telomere-targeting compounds. Underwriters are granted a 45-day option to purchase an additional 300,000 shares to cover overallotments.
MAIA Biotechnology, Inc. has priced its initial public offering of 2,000,000 shares at $5.00 each, expecting gross proceeds of $10,000,000. The shares will trade under the ticker symbol MAIA starting July 28, 2022, with the offering closing on August 1, 2022, pending customary conditions. The proceeds will fund Phase 2 trials for the product candidate THIO, pre-clinical development of new compounds, and general corporate purposes. ThinkEquity is managing the offering.